Long-term Efficacy of Contingency Management Treatment Based on Objective Indicators of Abstinence from Illicit Substance Use Up to 1 Year Following Treatment: A Meta-analysis

Overview

Journal J Consult Clin Psychol

Specialty Psychology

Date 2021 Jan 28

PMID 33507776

Citations 30

Authors

Meredith K Ginley

Rory A Pfund

Carla J Rash

Kristyn Zajac

Affiliations

Soon will be listed here.

Abstract

Objective: Contingency management (CM) is often criticized for limited long-term impact. This meta-analysis focused on objective indices of drug use (i.e., urine toxicology) to examine the effects of CM on illicit substance use up to 1 year following treatment.

Method: Analyses included randomized trials (k = 23) of CM for stimulant, opioid, or polysubstance use disorders that reported outcomes up to 1 year after the incentive delivery had ended. Using random effects models, odds ratios (OR) were calculated for the likelihood of abstinence. Metaregressions and subgroup analyses explored how parameters of CM treatment, namely escalation, frequency, immediacy, and magnitude of reinforcers, moderated outcomes.

Results: The overall likelihood of abstinence at the long-term follow-up among participants who received CM versus a comparison treatment (nearly half of which were community-based comprehensive therapies or protocol-based specific therapies) was OR = 1.22, 95% confidence interval [1.01, 1.44], with low to moderate heterogeneity (² = 36.68). Among 18 moderators, longer length of active treatment was found to significantly improve long-term abstinence.

Conclusions: CM showed long-term benefit in reducing objective indices of drug use, above and beyond other active, evidence-based treatments (e.g., cognitive-behavioral therapy, 12-step facilitation) and community-based intensive outpatient treatment. These data suggest that policymakers and insurers should support and cover costs for CM, which is the focus of hundreds of studies demonstrating its short-term efficacy and, now, additional data supporting its long-term efficacy. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Citing Articles

Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial.

Muyindike W, Fatch R, Lodi S, Emenyonu N, Kekibiina A, Adong J EClinicalMedicine. 2025; 80:103045.

PMID: 39867970 PMC: 11764067. DOI: 10.1016/j.eclinm.2024.103045.

Perspectives on Clinical Pharmacist-Delivered Contingency Management to Promote Smoking Abstinence Among Individuals with HIV: A Qualitative Study.

Bavishi P, Harsono D, Mistler C, Ledgerwood D, Bold K, Sigel K AIDS Behav. 2025; .

PMID: 39776014 DOI: 10.1007/s10461-024-04592-9.

A Qualitative Exploration of the Process and Experience of Change in Moving on in My Recovery: An Acceptance and Commitment Therapy Based Recovery Group for Substance Use Disorder.

Shepley E, Jackson M, Hogan L Behav Sci (Basel). 2025; 14(12.

PMID: 39767378 PMC: 11673865. DOI: 10.3390/bs14121237.

An initial randomized controlled trial of a Combined Medication and Behavioral Activation Treatment (CoMBAT) for people with opioid use disorder.

Hughto J, Hughes L, Nelson K, Perry N, Mimiaga M, Biello K J Subst Use Addict Treat. 2024; 169:209602.

PMID: 39672333 PMC: 11815587. DOI: 10.1016/j.josat.2024.209602.

Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal.

Schepis T Addiction. 2024; 120(2):251-252.

PMID: 39657706 PMC: 11707304. DOI: 10.1111/add.16725.

References

Rash C, DePhilippis D . Considerations for Implementing Contingency Management in Substance Abuse Treatment Clinics: The Veterans Affairs Initiative as a Model. Perspect Behav Sci. 2020; 42(3):479-499. PMC: 6768930. DOI: 10.1007/s40614-019-00204-3. View

Hjorthoj C, Hjorthoj A, Nordentoft M . Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances--systematic review and meta-analysis. Addict Behav. 2011; 37(3):225-33. DOI: 10.1016/j.addbeh.2011.11.025. View

Petry N, Weinstock J, Alessi S, Lewis M, Dieckhaus K . Group-based randomized trial of contingencies for health and abstinence in HIV patients. J Consult Clin Psychol. 2010; 78(1):89-97. PMC: 2813453. DOI: 10.1037/a0016778. View

Petry N, DePhilippis D, Rash C, Drapkin M, McKay J . Nationwide dissemination of contingency management: the Veterans Administration initiative. Am J Addict. 2014; 23(3):205-10. PMC: 3986725. DOI: 10.1111/j.1521-0391.2014.12092.x. View

Tiffany S, Friedman L, Greenfield S, Hasin D, Jackson R . Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction. 2011; 107(4):709-18. PMC: 3257402. DOI: 10.1111/j.1360-0443.2011.03581.x. View

Shoptaw S, Reback C, Peck J, Yang X, Rotheram-Fuller E, Larkins S . Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005; 78(2):125-34. DOI: 10.1016/j.drugalcdep.2004.10.004. View

Bradley H, Rucklidge J, Mulder R . A systematic review of trial registration and selective outcome reporting in psychotherapy randomized controlled trials. Acta Psychiatr Scand. 2016; 135(1):65-77. DOI: 10.1111/acps.12647. View

Magill M, Ray L . Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009; 70(4):516-27. PMC: 2696292. DOI: 10.15288/jsad.2009.70.516. View

Peace M, Tarnai L, Poklis A . Performance evaluation of four on-site drug-testing devices for detection of drugs of abuse in urine. J Anal Toxicol. 2000; 24(7):589-94. DOI: 10.1093/jat/24.7.589. View

10.

Petry N, Alessi S, Carroll K, Hanson T, Mackinnon S, Rounsaville B . Contingency management treatments: Reinforcing abstinence versus adherence with goal-related activities. J Consult Clin Psychol. 2006; 74(3):592-601. DOI: 10.1037/0022-006X.74.3.592. View

11.

Rawson R, McCann M, Flammino F, Shoptaw S, Miotto K, Reiber C . A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006; 101(2):267-74. DOI: 10.1111/j.1360-0443.2006.01312.x. View

12.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

13.

Griffith J, Roark R, SIMPSON D . Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000; 58(1-2):55-66. DOI: 10.1016/s0376-8716(99)00068-x. View

14.

Herbeck D, Hser Y, Teruya C . Empirically supported substance abuse treatment approaches: a survey of treatment providers' perspectives and practices. Addict Behav. 2008; 33(5):699-712. PMC: 2373985. DOI: 10.1016/j.addbeh.2007.12.003. View

15.

Chudzynski J, Roll J, McPherson S, Cameron J, Howell D . Reinforcement Schedule Effects on Long-Term Behavior Change. Psychol Rec. 2015; 65(2):347-353. PMC: 4484864. DOI: 10.1007/s40732-014-0110-3. View

16.

Silverman K, Robles E, Mudric T, Bigelow G, Stitzer M . A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. J Consult Clin Psychol. 2004; 72(5):839-54. DOI: 10.1037/0022-006X.72.5.839. View

17.

Donovan D, Bigelow G, Brigham G, Carroll K, Cohen A, Gardin J . Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction. 2011; 107(4):694-708. PMC: 3537825. DOI: 10.1111/j.1360-0443.2011.03473.x. View

18.

Petry N, Alessi S, Olmstead T, Rash C, Zajac K . Contingency management treatment for substance use disorders: How far has it come, and where does it need to go?. Psychol Addict Behav. 2017; 31(8):897-906. PMC: 5714694. DOI: 10.1037/adb0000287. View

19.

Stitzer M, Peirce J, Petry N, Kirby K, Roll J, Krasnansky J . Abstinence-based incentives in methadone maintenance: interaction with intake stimulant test results. Exp Clin Psychopharmacol. 2007; 15(4):344-50. DOI: 10.1037/1064-1297.15.4.344. View

20.

Kirby K, Benishek L, Dugosh K, Kerwin M . Substance abuse treatment providers' beliefs and objections regarding contingency management: implications for dissemination. Drug Alcohol Depend. 2006; 85(1):19-27. DOI: 10.1016/j.drugalcdep.2006.03.010. View